Answers are grounded in this paper and cite their sources.
The field of melanoma therapeutics has experienced a dramatic paradigm shift over the last 12 months through recent discoveries of novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. In this article, we review these findings and provide a framework to understand these discoveries, their significance in melanoma therapy, and role in clinical care. As this understanding grows, enduring therapeutic success may be achieved through tailored use of molecular markers and immunotherapies in sequential or combinatorial methods.
No takes yet. Share an insight, caveat, or question.
Hamid et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: